468 related articles for article (PubMed ID: 26851562)
1. Which Aspirin Dose and Preparation Is Best for the Long-Term Prevention of Cardiovascular Disease and Cancer? Evidence From a Systematic Review and Network Meta-Analysis.
Lotrionte M; Biasucci LM; Peruzzi M; Frati G; Giordano A; Biondi-Zoccai G
Prog Cardiovasc Dis; 2016; 58(5):495-504. PubMed ID: 26851562
[TBL] [Abstract][Full Text] [Related]
2. Aspirin for prophylactic use in the primary prevention of cardiovascular disease and cancer: a systematic review and overview of reviews.
Sutcliffe P; Connock M; Gurung T; Freeman K; Johnson S; Kandala NB; Grove A; Gurung B; Morrow S; Clarke A
Health Technol Assess; 2013 Sep; 17(43):1-253. PubMed ID: 24074752
[TBL] [Abstract][Full Text] [Related]
3. Aspirin for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: A Decision Analysis for the U.S. Preventive Services Task Force.
Dehmer SP; Maciosek MV; Flottemesch TJ; LaFrance AB; Whitlock EP
Ann Intern Med; 2016 Jun; 164(12):777-86. PubMed ID: 27064573
[TBL] [Abstract][Full Text] [Related]
4. Bleeding Risks With Aspirin Use for Primary Prevention in Adults: A Systematic Review for the U.S. Preventive Services Task Force.
Whitlock EP; Burda BU; Williams SB; Guirguis-Blake JM; Evans CV
Ann Intern Med; 2016 Jun; 164(12):826-35. PubMed ID: 27064261
[TBL] [Abstract][Full Text] [Related]
5. Aspirin for the Prevention of Cancer Incidence and Mortality: Systematic Evidence Reviews for the U.S. Preventive Services Task Force.
Chubak J; Whitlock EP; Williams SB; Kamineni A; Burda BU; Buist DS; Anderson ML
Ann Intern Med; 2016 Jun; 164(12):814-25. PubMed ID: 27064482
[TBL] [Abstract][Full Text] [Related]
6. Aspirin Use for the Primary Prevention of Cardiovascular Disease and Colorectal Cancer: U.S. Preventive Services Task Force Recommendation Statement.
Bibbins-Domingo K;
Ann Intern Med; 2016 Jun; 164(12):836-45. PubMed ID: 27064677
[TBL] [Abstract][Full Text] [Related]
7. Aspirin has potential benefits for primary prevention of cardiovascular outcomes in diabetes: updated literature-based and individual participant data meta-analyses of randomized controlled trials.
Seidu S; Kunutsor SK; Sesso HD; Gaziano JM; Buring JE; Roncaglioni MC; Khunti K
Cardiovasc Diabetol; 2019 Jun; 18(1):70. PubMed ID: 31159806
[TBL] [Abstract][Full Text] [Related]
8. Aspirin for the primary prevention of cardiovascular events: an update of the evidence for the U.S. Preventive Services Task Force.
Wolff T; Miller T; Ko S
Ann Intern Med; 2009 Mar; 150(6):405-10. PubMed ID: 19293073
[TBL] [Abstract][Full Text] [Related]
9. Aspirin for Primary Prevention of Cardiovascular Events.
Abdelaziz HK; Saad M; Pothineni NVK; Megaly M; Potluri R; Saleh M; Kon DLC; Roberts DH; Bhatt DL; Aronow HD; Abbott JD; Mehta JL
J Am Coll Cardiol; 2019 Jun; 73(23):2915-2929. PubMed ID: 31196447
[TBL] [Abstract][Full Text] [Related]
10. Aspirin for Primary Prevention of Atherosclerotic Cardiovascular Disease: Advances in Diagnosis and Treatment.
Mora S; Manson JE
JAMA Intern Med; 2016 Aug; 176(8):1195-204. PubMed ID: 27322595
[TBL] [Abstract][Full Text] [Related]
11. A comparison of contemporary versus older studies of aspirin for primary prevention.
Moriarty F; Ebell MH
Fam Pract; 2020 Jul; 37(3):290-296. PubMed ID: 31751455
[TBL] [Abstract][Full Text] [Related]
12. Individualised prediction of alternate-day aspirin treatment effects on the combined risk of cancer, cardiovascular disease and gastrointestinal bleeding in healthy women.
van Kruijsdijk RC; Visseren FL; Ridker PM; Dorresteijn JA; Buring JE; van der Graaf Y; Cook NR
Heart; 2015 Mar; 101(5):369-76. PubMed ID: 25475110
[TBL] [Abstract][Full Text] [Related]
13. Aspirin Efficacy in Primary Prevention: A Meta-analysis of Randomized Controlled Trials.
Barbarawi M; Kheiri B; Zayed Y; Gakhal I; Al-Abdouh A; Barbarawi O; Rashdan L; Rizk F; Bachuwa G; Alkotob ML
High Blood Press Cardiovasc Prev; 2019 Aug; 26(4):283-291. PubMed ID: 31280451
[TBL] [Abstract][Full Text] [Related]
14. Benefits and Risks Associated with Low-Dose Aspirin Use for the Primary Prevention of Cardiovascular Disease: A Systematic Review and Meta-Analysis of Randomized Control Trials and Trial Sequential Analysis.
Wang M; Yu H; Li Z; Gong D; Liu X
Am J Cardiovasc Drugs; 2022 Nov; 22(6):657-675. PubMed ID: 35570250
[TBL] [Abstract][Full Text] [Related]
15. Aspirin for Primary Prevention.
Richman IB; Owens DK
Med Clin North Am; 2017 Jul; 101(4):713-724. PubMed ID: 28577622
[TBL] [Abstract][Full Text] [Related]
16. Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither?
Patrono C
Eur Heart J; 2013 Nov; 34(44):3403-11. PubMed ID: 23771843
[TBL] [Abstract][Full Text] [Related]
17. Investigating the effectiveness of different aspirin dosing regimens and the timing of aspirin intake in primary and secondary prevention of cardiovascular disease: protocol for a systematic review.
Bem D; Dretzke J; Stevens S; Lordkipanidzé M; Hodgkinson J; Bayliss S; Moore D; Fitzmaurice D
Syst Rev; 2015 Jun; 4():88. PubMed ID: 26088608
[TBL] [Abstract][Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
